Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. (MNOV) generates frequent news as a clinical-stage biopharmaceutical company advancing late-stage small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Company announcements emphasize progress in its two core programs, MN-166 (ibudilast) and MN-001 (tipelukast), across multiple serious conditions.
News updates commonly cover clinical trial milestones, such as completion of patient enrollment, trial design details, and presentations at major scientific meetings. Examples include the COMBAT-ALS Phase 2b/3 trial of MN-166 in amyotrophic lateral sclerosis, the OXTOX study in chemotherapy-induced peripheral neuropathy, and the MN‑001‑NATG‑202 Phase 2 trial in hypertriglyceridemia and non-alcoholic fatty liver disease due to type 2 diabetes.
Investors and observers can also expect scientific and mechanistic updates, including peer-reviewed publications on MN-001 and its metabolite MN-002 in cholesterol and lipid metabolism, as well as letters from the CEO explaining how new data support the company’s development strategy. Regulatory and advisory appointments, such as the addition of experienced clinical and regulatory advisors, are another regular theme in MediciNova’s news flow.
Because MediciNova is listed on Nasdaq and the Tokyo Stock Exchange, its news often includes capital markets and investor relations events, such as conference presentations and corporate overviews for institutional and individual investors. This news page aggregates these developments so readers can follow clinical progress, scientific publications, regulatory interactions, and corporate updates related to MNOV in one place.
MediciNova, a biopharmaceutical company traded on NASDAQ (MNOV), announced that Geoffrey O'Brien will join a panel at the B. Riley FBR Virtual Infectious Disease Summit on July 21, 2020.
O'Brien will discuss treatment strategies for COVID-19, including the clinical development of MN-166 (ibudilast) aimed at preventing acute respiratory distress syndrome (ARDS). The FDA has accepted the Investigational New Drug Application for MN-166, allowing its clinical trial to proceed, focusing on hospitalized COVID-19 patients at risk for ARDS.
MediciNova, Inc. announced the FDA's acceptance of its Investigational New Drug Application (IND) for MN-166 (ibudilast), aimed at preventing Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. This opens the path for clinical trials targeting hospitalized patients at risk for ARDS, leveraging MN-166's anti-inflammatory and anti-thrombotic potential. The Phase 2 trial will assess safety, tolerance, and efficacy over 7 days, with key objectives focused on respiratory failure and plasma cytokine levels.
MediciNova announced positive preclinical findings for MN-166 (ibudilast) as an adjunct treatment for glioblastoma, published in Frontiers in Immunology. The study shows MN-166 effectively reduces myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, enhancing CD8 T cell activity. Clinical trials are underway combining MN-166 with temozolomide, showing improved survival rates in animal models. Glioblastoma is a severe brain cancer with a median survival of 11-15 months. MediciNova aims to revolutionize treatment options for this aggressive cancer.
MediciNova, Inc. announced the receipt of a Notice of Intention to Grant from the European Patent Office for a pending patent application covering MN-001 (tipelukast) and its metabolite MN-002. This patent will address treatments for hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia, expiring no earlier than July 2034. The patent claims include methods for reducing triglyceride and cholesterol blood levels through oral administration. This development could enhance the potential market value of MN-001, complementing existing patents in the U.S., Japan, and China.